Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Fusion Pharmaceuticals Inc. FUSN
$4.46
-$0.06 (-1.33%)
На 18:02, 12 мая 2023
+34.53%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
268584275.00000000
-
week52high
5.22
-
week52low
1.98
-
Revenue
1461000
-
P/E TTM
-2
-
Beta
-1.14654800
-
EPS
-1.85000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 12:30
Описание компании
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company has a strategic collaboration agreement with AstraZeneca UK Limited to jointly discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| William Blair | Outperform | 06 июл 2022 г. | |
| B. Riley Securities | Buy | 26 авг 2021 г. | |
| Morgan Stanley | Overweight | Overweight | 18 авг 2021 г. |
| Morgan Stanley | Overweight | Overweight | 18 мая 2021 г. |
| Morgan Stanley | Overweight | Overweight | 06 апр 2021 г. |
| Truist Securities | Buy | 16 сент 2022 г. | |
| JonesTrading | Buy | 07 сент 2022 г. | |
| SVB Leerink | Outperform | 30 ноя 2022 г. | |
| Morgan Stanley | Overweight | Overweight | 27 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Valliant John | A | 500000 | 500000 | 05 янв 2023 г. |
| Burak Eric | A | 250000 | 250000 | 05 янв 2023 г. |
| Crowley John J | A | 250000 | 250000 | 05 янв 2023 г. |
| Leamon Christopher P | A | 250000 | 250000 | 05 янв 2023 г. |
| Rawat Mohit | A | 300000 | 300000 | 05 янв 2023 г. |
| Khuong Chau Quang | A | 42093 | 42093 | 11 ноя 2022 г. |
| Bobilev Dmitri | A | 550000 | 550000 | 07 ноя 2022 г. |
| GANNON STEVEN | A | 56400 | 44400 | 11 авг 2022 г. |
| Preston Heather | A | 17000 | 17000 | 14 июн 2022 г. |
| Lee Philina | A | 17000 | 17000 | 14 июн 2022 г. |
Новостная лента
Fusion Pharmaceuticals Inc. (FUSN) Reports Q3 Loss, Lags Revenue Estimates
Zacks Investment Research
08 ноя 2022 г. в 09:47
Fusion Pharmaceuticals Inc. (FUSN) delivered earnings and revenue surprises of -5.77% and 66.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
5 Stocks to Bet on in an Innovation-Driven Drug Industry
Zacks Investment Research
20 окт 2022 г. в 12:02
Innovation is expected continue driving growth in the Medical-Drugs industry in 2023. JAZZ, CPRX, AERI, LRMR and FUSN may prove to be good additions to one's portfolio.
What Makes Fusion Pharmaceuticals Inc. (FUSN) a New Strong Buy Stock
Zacks Investment Research
13 окт 2022 г. в 13:33
Fusion Pharmaceuticals Inc. (FUSN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
After Plunging 14.9% in 4 Weeks, Here's Why the Trend Might Reverse for Fusion Pharmaceuticals Inc. (FUSN)
Zacks Investment Research
12 авг 2022 г. в 11:17
Fusion Pharmaceuticals Inc. (FUSN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Fusion Pharmaceuticals Inc. (FUSN) Reports Q2 Loss, Tops Revenue Estimates
Zacks Investment Research
09 авг 2022 г. в 09:47
Fusion Pharmaceuticals Inc. (FUSN) delivered earnings and revenue surprises of 16.98% and 3.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?